Supplemental Fig
The many alternatives now enable healthcare practitioners to customise the formulation and delivery method according to specific patient preferences and requirements
From late 2022 through early 2025, widespread supply constraints prompted the FDA to permit compounding under Sections 503A and 503B of the Food, Drug, and Cosmetic Act
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial)
The sales page and FAQ say "refund with no questions asked," but the Terms & Conditions reference returns for "damaged" products specifically
The altered homeostatic incretin levels in PAR2-G37I or PAR2-R38E versus WT mice were not caused by apparent changes in metabolism, as no significant differences in food and fluid intake, energy expenditure, respiratory exchange ratio, or locomotor activity were observed in indirect calorimetry (Supplemental Figure 2, A and B)